Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04028713
Other study ID # BIOLOPTIM-ADA
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date February 16, 2021
Est. completion date March 22, 2022

Study information

Verified date December 2019
Source University Hospital, Ghent
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The optimal therapeutic serum trough level (Ctrough) of adalimumab was defined between 3,5 and 7,0 µg/ml in patients with plaque type psoriasis. An adalimumab Ctrough above this therapeutic range did not add clinical response. Based on this therapeutic window, the introduction of dose adjustments based on Ctroughs (therapeutic drug monitoring) will be further validated in a prospective randomized-controlled trial. Here, we aim to determine whether, in patients with a good clinical response and supratherapeutic adalimumab Ctroughs, dose reduction is able to maintain favorable clinical outcome.


Description:

Patients will be included after signing informed consent and randomized in either a standard dose arm or a concentration based arm based on prior Ctrough measurements. In the concentration based arm, dosing frequency will be lowered to once every 3 weeks. If patients still have supratherapeutic Ctroughs of adalimumab, these patients will continue adalimumab self-administration every 4 weeks. In the standard based arm, patients will continue on standard dosing schedule. During each study visit blood will be taken in order to quantify Ctroughs. In addition, Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA) score will be evaluated by a physician. Patients complete the Dermatology Life Quality Index (DLQI) and European quality of life EQ-5D instrument at each visit. In addition, in a subset of patients in each treatment arm, additional sampling will be collected by dried blood spot sampling in order to build a PK(PD) model for adalimumab.


Recruitment information / eligibility

Status Terminated
Enrollment 19
Est. completion date March 22, 2022
Est. primary completion date March 22, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis for at least 6 months prior to inclusion 2. Participants must have a stable disease during maintenance on adalimumab (absolute PASI < 3) 3. Participants are not allowed to use topical steroids from 7 days before randomization until the end of the study (week 48). 4. Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study Exclusion Criteria: 1. Participants who have currently a predominant nonplaque form of psoriasis 2. Participants who are pregnant, nursing or planning a pregnancy while enrolled in the study or within 12 weeks after receiving the last administration of study intervention 3. Participants who are unable or unwilling to undergo multiple venapunctures 4. Participants who are treated according to a different dosing schedule than standard dosing of adalimumab (regular dose regimen every 2 weeks; 40 mg)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Venapuncture
Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.
Dried blood spot
A subset of patients will sample additionally by using the dried blood sampling technique.
Drug:
Dose reduction
Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.

Locations

Country Name City State
Belgium AZ Sint-Jan Brugge West-Vlaanderen
Belgium AZ Maria Middelares Ghent East-Flanders
Belgium AZ Sint-Lucas Ghent East-Flanders
Belgium University Hospital Ghent Ghent East-Flanders
Belgium University Hospital Leuven Leuven Vlaams-Brabant
Belgium Private practice Dermatology Maldegem East-Flanders
Belgium AZ Delta Rembert Torhout West-Flanders

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Ghent KU Leuven, University Ghent

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

Soenen R, Stove C, Capobianco A, De Schutter H, Dobbelaere M, Mahjor T, Follens M, Lambert J, Grine L. Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice. J Clin Med. 2022 May 26;11(11):3011. doi: 10.3390/jcm11113011 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical response The proportion of patients in each group in clinical remission (absolute PASI < 2) at year 1 after optimization Week 0- Week 48
Secondary The proportion of patients in each group with serum trough levels of adalimumab within the optimal interval. Week 0- Week 48
Secondary The proportion of patients in each group with anti-drug antibodies (ADA) against adalimumab. Week 0- Week 48
Secondary Relapse The proportion of patients in each group who relapses (defined as the need for dose escalation (not in the standard based dosing arm)) Week 0- Week 48
See also
  Status Clinical Trial Phase
Completed NCT03669757 - Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis Phase 1
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Completed NCT03584360 - Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin Phase 2
Recruiting NCT04994951 - Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome. Phase 2
Completed NCT02888236 - LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris Phase 2
Completed NCT02533973 - Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Phase 4
Completed NCT02193815 - A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis Phase 1
Completed NCT02004847 - Blue Light for Treating Psoriasis Vulgaris N/A
Completed NCT01946386 - A Vasoconstriction Study With LEO 90100 Phase 1
Recruiting NCT01443338 - Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 Phase 4
Completed NCT01188928 - LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) Phase 3
Completed NCT00764751 - Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris Phase 2
Completed NCT00236171 - Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test N/A
Completed NCT04541329 - Predicting Inflammatory Skin Disease Response to IL-23 Blockade Phase 4
Completed NCT06064084 - Incretin Effect in Patients With Psoriasis and Controls
Not yet recruiting NCT06398106 - Proactive TDM Versus Standard Use of Biologics in Psoriasis Phase 4
Recruiting NCT05390515 - Psoriatic Immune Response to Tildrakizumab Phase 4
Recruiting NCT05892640 - Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis N/A
Recruiting NCT04950218 - The Psoriasis Echo Study
Completed NCT05184348 - Plexin B2 Gene Expression and Polymorphisms in Psoriasis Phase 1

External Links